BioVie Inc. Reports $5.3 Million Net Loss for Q1 2026, Driven by Increased R&D Expenses

BioVie Inc. reported a net loss of approximately $5.3 million for the three months ended March 31, 2026, compared to a net loss of about $2.8 million for the same period in 2025. This increase of $2.5 million was primarily driven by a rise in research and development (R&D) expenses, which totaled approximately $3.2 million, up from $1.3 million in the prior year. The company's total operating expenses for the quarter reached approximately $5.4 million, significantly higher than the $3.0 million reported in the previous year. For the nine months ended March 31, 2026, the net loss was approximately $16.4 million, compared to $14.1 million for the same period in 2025, reflecting a similar trend in increased operating expenses.

The increase in R&D expenses was largely attributed to heightened activity in clinical studies, particularly the Phase 2b trial of bezisterim for Parkinson's Disease and the Long COVID Phase 2 study. The costs associated with the Sunrise PD Phase 2 study rose to approximately $2.1 million, while the Long COVID study incurred costs of about $2.6 million. The company also recognized grant reimbursements of approximately $3.1 million for R&D expenses during the quarter, compared to $2.5 million in the same period last year. General and administrative expenses also increased, totaling approximately $2.2 million for the quarter, up from $1.6 million in the prior year.

As of March 31, 2026, BioVie reported total assets of approximately $17.5 million, down from $21.6 million as of June 30, 2025. The decrease in assets was primarily due to a reduction in cash and cash equivalents, which fell to approximately $13.1 million from $17.5 million. The company's liabilities also decreased, totaling approximately $1.9 million, down from $2.6 million in the previous fiscal period. Stockholders' equity was reported at approximately $15.6 million, a decline from $19.0 million as of June 30, 2025, largely due to the accumulated deficit of approximately $368.6 million.

In terms of strategic developments, BioVie has been actively pursuing clinical trials for its drug candidates, including bezisterim, which is being evaluated for its potential to treat neurodegenerative diseases and long COVID. The company has also secured a $13.1 million grant from the U.S. Department of Defense to support its Long COVID program. Despite these advancements, BioVie remains in the pre-revenue stage, with no revenues expected in the foreseeable future. The company is focused on securing additional financing to support its ongoing operations and clinical development efforts, with management indicating that future funding may come from equity sales or other strategic transactions.

Looking ahead, BioVie anticipates reporting topline results from the Phase 2b trial of bezisterim in mid-2026, although the timing is subject to change. The company continues to face significant challenges, including the need for additional capital to fund its operations and the uncertainties associated with clinical trial outcomes and regulatory approvals. Management has expressed that while they are pursuing strategic plans, there is no assurance of success in obtaining sufficient financing, raising substantial doubt about the company's ability to continue as a going concern.